Gilead starts trial for its autoimmune disease drug in KOR
By Lee, Hye-Kyung | translator Alice Kang
24.12.20 05:00:51
가나다라
0
MFDS approves Phase Ib trial...first clinical trial in Asia following trials in the U.S. and U.K.
The B- and T-Lymphocyte Attenuator (BTLA) autoimmune disease treatment will enter clinical trials in Korea.
The Ministry of Food and Drug Safety approved Gilead Sciences' application for a ‘multicenter, randomized, placebo-controlled Phase 1b clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of multiple ascending doses of GS-0272 in adult participants with rheumatoid arthritis.’
The trial will be conducted at Chungnam National University Hospital, Seoul National University Hospital, and Ajou University Hospital.
Gilead has been conducting a Phase I trial on GS-0272 since September 2023 in the United States
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)